CCNE2

G1/S-specific cyclin-E2

68,808 patent compounds predicted against CCNE2, 45,971 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL12466	0.58	16/20
SCHEMBL12292	0.59	14/20
SCHEMBL179490	0.52	12/20
SCHEMBL412212	0.66	11/20
SCHEMBL409805	0.64	11/20
SCHEMBL408691	0.61	11/20
SCHEMBL411266	0.59	11/20
Clonazepam (SCHEMBL357481)	0.47	11/20
SCHEMBL160631	0.40	11/20
SCHEMBL407802	0.71	10/20
Hydrochloric Acid (SCHEMBL411390)	0.70	10/20
SCHEMBL411857	0.70	10/20
SCHEMBL411037	0.69	10/20
Hydrochloric Acid (SCHEMBL410806)	0.68	10/20
SCHEMBL410132	0.68	10/20
SCHEMBL411691	0.68	10/20
SCHEMBL413176	0.67	10/20
Hydrochloric Acid (SCHEMBL411919)	0.67	10/20
Hydrochloric Acid (SCHEMBL412197)	0.67	10/20
Clonazepam (SCHEMBL38899)	0.59	10/20

Germline variants in CCNE2 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full CCNE2 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to CCNE2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt	PHASE4	COMPLETED
Effect of Silymarin in Metastatic Colorectal Cancer Patients	PHASE3	UNKNOWN
Study of AVZO-021 in Patients With Advanced Solid Tumors	PHASE1/PHASE2	RECRUITING
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas	PHASE2	RECRUITING
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer	PHASE2	RECRUITING
Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage	PHASE2	RECRUITING
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor	PHASE1/PHASE2	RECRUITING
Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy	PHASE2	COMPLETED
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer	PHASE2	UNKNOWN
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)	PHASE1/PHASE2	RECRUITING
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression	PHASE2	COMPLETED
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors	PHASE1/PHASE2	RECRUITING
Green Tea Extract in Preventing Cancer in Former and Current Heavy Smokers With Abnormal Sputum	PHASE2	COMPLETED
Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma	PHASE1/PHASE2	RECRUITING
Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)	PHASE2	UNKNOWN
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers	PHASE1/PHASE2	COMPLETED
Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors	PHASE1/PHASE2	WITHDRAWN
Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients	PHASE2	COMPLETED
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors	PHASE1	RECRUITING
Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)	PHASE1	SUSPENDED
Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms	PHASE1	COMPLETED
Study of FCN-437c in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)	PHASE1	COMPLETED
the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy	nan	UNKNOWN
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer	nan	UNKNOWN
Co'Moon for Supporting Breast Cancer Patients on Adjuvant Endocrine Therapy	nan	COMPLETED
Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.	nan	RECRUITING
QOL of Women With HR-Positive Metastatic BC Treated in the First-line Setting: Comparison Between Public and Private Institutions.	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CCNE2 binder may also engage these)

Protein	Name	Similarity
Q9Z238	—	1.000	Q9Z238 →
Q5E9K7	—	0.998	Q5E9K7 →
P50756	—	0.996	P50756 →
Q91780	—	0.996	Q91780 →
Q61457	—	0.993	Q61457 →
CCNE1	G1/S-specific cyclin-E1	0.993	landscape →
P49707	—	0.992	P49707 →
P39949	—	0.991	P39949 →
O42575	—	0.991	O42575 →
P47794	—	0.990	P47794 →
O15995	—	0.985	O15995 →
P55169	—	0.983	P55169 →
Q16589	—	0.983	Q16589 →
P25322	—	0.983	P25322 →
Q32NM1	—	0.981	Q32NM1 →
Q90459	—	0.981	Q90459 →
Q64HP0	—	0.981	Q64HP0 →
Q8WNW2	—	0.980	Q8WNW2 →
P39948	—	0.980	P39948 →
Q0P5D3	—	0.980	Q0P5D3 →
CCND1	G1/S-specific cyclin-D1	0.980	landscape →
Q9SA32	—	0.979	Q9SA32 →
Q52QT8	—	0.979	Q52QT8 →
Q2KI22	—	0.978	Q2KI22 →
Q04827	—	0.978	Q04827 →
CCND2	G1/S-specific cyclin-D2	0.978	landscape →
P49706	—	0.978	P49706 →
P51945	—	0.976	P51945 →
Q9D995	—	0.976	Q9D995 →
P30280	—	0.976	P30280 →